enGene Holdings reported a Q4 2024 net loss of $15.3 million with no revenue disclosed for the period, consistent with a clinical-stage biotechnology company advancing a gene therapy platform. R&D spending remained the primary driver of operating expenses, totaling $11.273 million, with G&A of $7.7 million, culminating in operating expenses of $17.455 million and EBITDA of negative $14.441 million. Cash burn was evident as cash from operations amounted to −$19.568 million and free cash flow was −$19.806 million. The company concluded the quarter with $173.0 million in cash and cash equivalents and a net cash position of approximately −$148.0 million in net debt terms, reflecting a strong liquidity state despite ongoing cash utilization.
A material financing event in Q4 included issuance of common stock generating approximately $60.2 million of cash from financing activities, partially offsetting cash used in operations and investing. Total assets stood at $311.2 million with stockholders’ equity of $272.6 million and limited near-term debt (total debt of $25.0 million). This balance sheet configuration provides runway to advance EG70 and related pipeline activities, but the lack of topline revenue emphasizes the need for milestone progress or strategic partnerships to support longer-term value creation. Management commentary from the earnings release is not included in the provided data; inferences rely on the disclosed financials and typical industry dynamics for pre-revenue gene therapy programs.
Overall, the QQ4 2024 results reflect a typical pre-revenue, clinical-stage biotech profile: significant R&D intensity, reliance on external funding to sustain operations, and a cash-rich balance sheet that offers runway to pursue clinical milestones and potential strategic collaborations.